rs1555742243

Variant summary

Our verdict is Uncertain significance. The variant received 1 ACMG points: 2P and 1B. PM2BP4

The NM_004364.5(CEBPA):​c.256C>T​(p.Arg86Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000279 in 1,435,626 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R86Q) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.000020 ( 0 hom., cov: 32)
Exomes 𝑓: 7.8e-7 ( 0 hom. )

Consequence

CEBPA
NM_004364.5 missense

Scores

3
5
11

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:2

Conservation

PhyloP100: 1.03

Publications

0 publications found
Variant links:
Genes affected
CEBPA (HGNC:1833): (CCAAT enhancer binding protein alpha) This intronless gene encodes a transcription factor that contains a basic leucine zipper (bZIP) domain and recognizes the CCAAT motif in the promoters of target genes. The encoded protein functions in homodimers and also heterodimers with CCAAT/enhancer-binding proteins beta and gamma. Activity of this protein can modulate the expression of genes involved in cell cycle regulation as well as in body weight homeostasis. Mutation of this gene is associated with acute myeloid leukemia. The use of alternative in-frame non-AUG (GUG) and AUG start codons results in protein isoforms with different lengths. Differential translation initiation is mediated by an out-of-frame, upstream open reading frame which is located between the GUG and the first AUG start codons. [provided by RefSeq, Dec 2013]
CEBPA-DT (HGNC:25710): (CEBPA divergent transcript)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Uncertain_significance. The variant received 1 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.34892172).

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CEBPANM_004364.5 linkc.256C>T p.Arg86Trp missense_variant Exon 1 of 1 ENST00000498907.3 NP_004355.2 P49715-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CEBPAENST00000498907.3 linkc.256C>T p.Arg86Trp missense_variant Exon 1 of 1 6 NM_004364.5 ENSP00000427514.1 P49715-1
CEBPA-DTENST00000718467.1 linkn.46+360G>A intron_variant Intron 1 of 1
ENSG00000267727ENST00000587312.1 linkn.*219G>A downstream_gene_variant 3

Frequencies

GnomAD3 genomes
AF:
0.0000198
AC:
3
AN:
151380
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000726
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD4 exome
AF:
7.79e-7
AC:
1
AN:
1284246
Hom.:
0
Cov.:
33
AF XY:
0.00000158
AC XY:
1
AN XY:
631960
show subpopulations
African (AFR)
AF:
0.0000377
AC:
1
AN:
26496
American (AMR)
AF:
0.00
AC:
0
AN:
25256
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
21906
East Asian (EAS)
AF:
0.00
AC:
0
AN:
27530
South Asian (SAS)
AF:
0.00
AC:
0
AN:
64052
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
44834
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5172
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
1017138
Other (OTH)
AF:
0.00
AC:
0
AN:
51862
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.525
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome
AF:
0.0000198
AC:
3
AN:
151380
Hom.:
0
Cov.:
32
AF XY:
0.0000135
AC XY:
1
AN XY:
73918
show subpopulations
African (AFR)
AF:
0.0000726
AC:
3
AN:
41332
American (AMR)
AF:
0.00
AC:
0
AN:
15226
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3468
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5084
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4832
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10330
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
312
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
67816
Other (OTH)
AF:
0.00
AC:
0
AN:
2072
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.542
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00
Hom.:
0
Bravo
AF:
0.00000756

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Inborn genetic diseases Uncertain:1
Feb 14, 2025
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.R86W variant (also known as c.256C>T), located in coding exon 1 of the CEBPA gene, results from a C to T substitution at nucleotide position 256. The arginine at codon 86 is replaced by tryptophan, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. -

Acute myeloid leukemia Uncertain:1
Oct 22, 2023
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 86 of the CEBPA protein (p.Arg86Trp). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CEBPA-related conditions. ClinVar contains an entry for this variant (Variation ID: 526811). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CEBPA protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.62
BayesDel_addAF
Benign
-0.17
T
BayesDel_noAF
Benign
-0.48
CADD
Pathogenic
26
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.53
D
Eigen
Benign
0.0085
Eigen_PC
Benign
0.061
FATHMM_MKL
Uncertain
0.82
D
LIST_S2
Uncertain
0.88
D
M_CAP
Pathogenic
0.95
D
MetaRNN
Benign
0.35
T
MetaSVM
Benign
-1.1
T
MutationAssessor
Benign
0.0
N
PhyloP100
1.0
PrimateAI
Pathogenic
0.95
D
PROVEAN
Benign
-2.0
N
REVEL
Benign
0.093
Sift
Uncertain
0.017
D
Sift4G
Benign
0.085
T
Polyphen
0.99
D
Vest4
0.13
MutPred
0.32
Loss of disorder (P = 0.0195);
MVP
0.48
ClinPred
0.73
D
GERP RS
3.0
PromoterAI
-0.063
Neutral
Varity_R
0.14
gMVP
0.29
Mutation Taster
=80/20
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1555742243; hg19: chr19-33793065; API